SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) today announced positive results from a Phase 1 clinical trial of XP21279, a Transported Prodrug of levodopa, or L-Dopa. The trial compared the pharmacokinetic (PK) profile of L-Dopa produced by a single oral dose of a prototype, sustained-release tablet of XP21279 to that of a near-equivalent single dose of oral L-Dopa. The trial demonstrated that XP21279 produced a more sustained exposure of L-Dopa compared to oral L-Dopa dosed in the same healthy subjects. XP21279 was well-tolerated in this first trial in humans.
